LIMN News & Events

Liminatus Pharma announced the pricing of its best-efforts public offering of 13,813,000 shares of its common stock and warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share and accompanying warrants. The warrants will have an exercise price of $0.29 per share, will be exercisable immediately upon issuance and will expire on the fifth anniversary of the original issuance date. The closing of the offering is expected to occur on or about February 18, 2026, subject to the satisfaction of customary closing conditions. Gross proceeds, before deducting placement agent fees and other estimated offering expenses, are expected to be approximately $4M. The potential additional gross proceeds to the Company from the exercise of the warrants, if fully exercised on a cash basis, would be approximately $6.0 million. No assurance can be given that any warrants will be exercised. Maxim Group is acting as sole placement agent in connection with this offering.

Liminatus Pharma announced plans for a strategic expansion into the cryptocurrency and blockchain sector. The company intends to establish a dedicated subsidiary, named "American BNB Strategy," to lead its digital asset investment and management initiatives. Through this planned vehicle, Liminatus aims to raise and deploy up to $500 million in phases, targeting strategic, long-term investments in BNB coin the native token of the Binance ecosystem, the world's largest digital asset exchange. This announcement follows an internal review of blockchain-integrated financial strategies conducted over the past several weeks.

Liminatus Pharma announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated digital asset investment vehicle. The prospective subsidiary-which has not yet been formed and remains under active consideration-would operate independently of Liminatus's core clinical pipeline and focus on digital asset allocation and blockchain-integrated financial structures. If approved and executed, the Company anticipates targeting up to $500M in potential capital formation through a combination of private placements, convertible instruments, equity line and other structured financing tools. All fundraising activities, if undertaken, would be conducted in full alignment with applicable SEC regulations and exemptions. At this stage, no capital has been raised or committed, no agreements have been executed, and no third-party partnerships have been established. The internal review remains subject to final Board approval, regulatory compliance, and prevailing market conditions. Liminatus is working in close coordination with experienced legal, financial, and regulatory advisors to determine the optimal structure, governance, and compliance framework for the proposed initiative. The Company will provide further disclosures as appropriate, in accordance with SEC and Nasdaq reporting requirements.